Bevacizumab
- Generic Name
- Bevacizumab
- Brand Names
- Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216974-75-3
- Unique Ingredient Identifier
- 2S9ZZM9Q9V
- Background
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...
- Indication
As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...
- Associated Conditions
- Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Associated Therapies
- First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT05908786
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇺🇸University of Southern California (USC); Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California Los Angeles (UCLA) - Cancer Care - Santa Monica, Santa Monica, California, United States
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 650
- Registration Number
- NCT05904886
- Locations
- 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸UCLA MEDICAL CENTER; Alhambra, Alhambra, California, United States
🇺🇸UCSF Fresno at Community Cancer Institute, Clovis, California, United States
A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT05904457
- Locations
- 🇰🇷
Cha University Bundang Medical Center, Seongnam, Gyeonggi-do, Korea, Republic of
🇰🇷Chungnam National University Hospital, Daejeon, Chungcheongnam-do, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Shi Ming
- Registration Number
- NCT05886257
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 40
- Registration Number
- NCT05886465
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05869097
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 408
- Registration Number
- NCT05863195
- Locations
- 🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 25
- Registration Number
- NCT05854498
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 155
- Registration Number
- NCT05843188
- Locations
- 🇨🇦
Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 818
- Registration Number
- NCT05839951
- Locations
- 🇺🇸
Many locations, Whippany, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.